| Cell line name |
HCT 116_184R |
|---|
| Synonyms |
H184-R |
|---|
| Accession |
CVCL_C3GH |
|---|
| Resource Identification Initiative |
To cite this cell line use: HCT 116_184R (RRID:CVCL_C3GH) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:91353; 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide (CI-1040; PD184352).
Derived from site: In situ; Colon; UBERON=UBERON_0001155. |
|---|
| Sequence variations |
- Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 9277; PPM1D; Simple; p.Leu450Ter (c.1349delT) (p.Leu450fs) (c.1344delT); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Colon carcinoma (NCIt: C4910) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0291 (HCT 116) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
48Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=21447798; DOI=10.1126/scisignal.2001752
Little A.S., Balmanno K., Sale M.J., Newman S., Dry J.R., Hampson M., Edwards P.A.W., Smith P.D., Cook S.J.
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Sci. Signal. 4:Ra17.1-Ra17.15(2011) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_C3GH
|
|---|
| Encyclopedic resources |
Wikidata; Q114311570
|
|---|
| Entry history |
|---|
| Entry creation | 22-Sep-2022 |
|---|
| Last entry update | 05-Oct-2023 |
|---|
| Version number | 5 |
|---|
